Syndax Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-2.964; its P/E ratio is -6.91; Syndax Pharmaceuticals is scheduled to report earnings on May 6, 2024, and the estimated EPS forecast is $-0.99. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	$ -72.41M	$ -51.08M	$ -44.58M	$ -46.16M	$ -42.14M
EBITDA	$ -75.87M	$ -54.73M	$ -48.30M	$ -50.13M	$ -44.16M
Net Income Common Stockholders	$ -72.47M	$ -51.15M	$ -44.62M	$ -41.13M	$ -39.19M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 570.70M	$ 363.56M	$ 398.80M	$ 438.20M	$ 484.40M
Total Assets	$ 612.88M	$ 399.22M	$ 431.34M	$ 459.81M	$ 497.24M
Total Debt	$ 1.61M	$ 1.85M	$ 2.07M	$ 1.04M	$ 1.14M
Net Debt	$ -569.09M	$ -361.71M	$ -396.73M	$ -437.16M	$ -483.25M
Total Liabilities	$ 58.68M	$ 40.04M	$ 31.30M	$ 24.32M	$ 29.79M
Stockholders Equity	$ 554.20M	$ 359.19M	$ 400.04M	$ 435.50M	$ 467.45M
Cash Flow	-
Free Cash Flow	$ -41.35M	$ -44.65M	$ -35.37M	$ -39.23M	$ -22.89M
Operating Cash Flow	$ -41.35M	$ -44.65M	$ -35.37M	$ -39.23M	$ -22.89M
Investing Cash Flow	$ -16.29M	$ 40.08M	$ 73.91M	$ 19.91M	$ -137.63M
Financing Cash Flow	$ 258.48M	$ 1.85M	$ 1.32M	$ 2.47M	$ 163.50M

Currency in USD

Syndax Pharmaceuticals Earnings and Revenue History

Income Statement >

Syndax Pharmaceuticals Debt to Assets

Balance Sheet >

Syndax Pharmaceuticals Cash Flow

Cash Flow >

Syndax Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing